DIFFERENCES BETWEEN ANTIPSYCHOTIC-DRUGS IN PERSISTENCE OF BRAIN LEVELS AND BEHAVIORAL-EFFECTS

被引:57
作者
COHEN, BM
TSUNEIZUMI, T
BALDESSARINI, RJ
CAMPBELL, A
BABB, SM
机构
[1] Mailman Research Center, McLean Hospital, Belmont, 02178, MA
关键词
HALOPERIDOL; BRAIN LEVELS; BROMPERIDOL; CHLORPROMAZINE; FLUPHENAZINE;
D O I
10.1007/BF02245121
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
After a single dose of the butyrophenone neuroleptic haloperidol, behavioral effects and detectable drug levels in rat brain can last for several weeks. To determine if such persistence is a general property of neuroleptics, we compared drug levels and effects after IP administration of two butyrophenones (haloperidol and bromperidol), a high potency (fluphenazine) and a low potency (chlorpromazine) phenothiazine. Drug levels in brain tissue were measured by high pressure liquid chromatography and behavioral effects monitored as inhibition of apomorphine-induced stereotypy. Estimated near terminal elimination half-lives (t 1/2) from brain for acutely administered chlorpromazine (20 mg/kg) and fluphenazine (1 mg/kg) were 0.41 and 0.62 days, respectively, and neither drug was detectable after 4 days. Fluphenazine given daily for 5 days showed an only slightly slower elimination (t 1/2 = 1.1 days). In contrast, near-terminal elimination half-lives from brain for haloperidol and bromperidol (both at 1 mg/kg, IP) were much longer (6.6 and 5.8 days, respectively), and each was detectable for 21 days after dosing. Inhibition of apomorphine-induced stereotypy correlated highly (r = 0.95) with brain levels of haloperidol. For fluphenazine, given once or repeatedly, early inhibition was replaced within 1 week by supersensitivity to apomorphine which persisted for up to 3 weeks. These findings, indicating marked differences in clearance and recovery times after dosing with butyrophenones and phenothiazines, have clear implications for studies of the effects of neuroleptic drugs in rats. While there are limits to the extrapolation of these findings to other species, our results and those from studies in human subjects suggest similarly persistent drug levels and effects may be seen when patients are withdrawn from neuroleptic drugs.
引用
收藏
页码:338 / 344
页数:7
相关论文
共 48 条
[31]  
LEVINE J, 1980, LONG TERM EFFECTS NE, P483
[32]  
LEWI PJ, 1970, ARZNEI-FORSCHUNG, V20, P943
[33]  
LUTZ EG, 1965, DIS NERV SYST, V26, P355
[34]  
MIDHA KK, 1988, PSYCHOPHARMACOLOGY, V96, P206
[35]   DOPAMINERGIC SUPER-SENSITIVITY AFTER NEUROLEPTICS - TIME-COURSE AND SPECIFICITY [J].
MULLER, P ;
SEEMAN, P .
PSYCHOPHARMACOLOGY, 1978, 60 (01) :1-11
[36]   NEUROMETABOLIC AND BEHAVIORAL-EFFECTS OF HALOPERIDOL IN RELATION TO DRUG LEVELS IN SERUM AND BRAIN [J].
OHMAN, R ;
LARSSON, M ;
NILSSON, IM ;
ENGEL, J ;
CARLSSON, A .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1977, 299 (02) :105-114
[37]   CHRONIC HALOPERIDOL AFFECTS STRIATAL D2-DOPAMINE RECEPTOR REAPPEARANCE AFTER IRREVERSIBLE RECEPTOR BLOCKADE [J].
PICH, EM ;
BENFENATI, F ;
FARABEGOLI, C ;
FUXE, K ;
MELLER, E ;
ARONSSON, M ;
GOLDSTEIN, M ;
AGNATI, LF .
BRAIN RESEARCH, 1987, 435 (1-2) :147-152
[38]  
PICKAR D, 1986, ARCH GEN PSYCHIAT, V43, P669
[39]  
SAKALIS G, 1972, CLIN PHARMACOL THER, V13, P931
[40]   ANTI-SCHIZOPHRENIC DRUGS - MEMBRANE RECEPTOR-SITES OF ACTION [J].
SEEMAN, P .
BIOCHEMICAL PHARMACOLOGY, 1977, 26 (19) :1741-1748